Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.54 |
| ▸ | VNN1 | O95497 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10211615 | 0.85 | EPHX2 (0.64) | SIGMAR1EPHX2ALDH1A1 | |
| SCHEMBL12726019 | 0.83 | SIGMAR1 (0.68) | SIGMAR1CYP1A2CYP3A4CYP2C9KDM4E | |
| SCHEMBL23972940 | 0.82 | EPHX2 (0.68) | SIGMAR1CYP1A2CYP3A4CYP2C9KDM4E | |
| SCHEMBL10212594 | 0.81 | ALDH1A1 (0.58) | ALDH1A1 | |
| SCHEMBL10211589 | 0.79 | POLB (0.69) | CYP1A2CYP3A4POLBEPHX2ALDH1A1 | |
| SCHEMBL359497 | 0.78 | ALDH1A1 (0.51) | CHRM2CHRM1CHRM3CYP2C9ALDH1A1 | |
| SCHEMBL13621159 | 0.77 | SIGMAR1 (0.58) | SIGMAR1HRH3ALDH1A1 | |
| SCHEMBL22868465 | 0.77 | EPHX2 (0.56) | SIGMAR1EPHX2 | |
| SCHEMBL25946512 | 0.76 | SIGMAR1 (0.59) | SIGMAR1CYP1A2CYP3A4CYP2C9KDM4E | |
| SCHEMBL19132725 | 0.75 | SIGMAR1 (0.61) | SIGMAR1CYP1A2CYP3A4CYP2C9EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | SIGMAR1 4493/4885CHRM2 2858/4885CHRM1 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.